Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer
This study has been terminated.
(Due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited clinical responses.)
Sponsor:
University of Alabama at Birmingham
Collaborator:
GlaxoSmithKline
Information provided by:
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00317434
First received: April 20, 2006
Last updated: December 10, 2009
Last verified: December 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | April 2007 |
| Primary Completion Date: | March 2007 (Final data collection date for primary outcome measure) |